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Abstract
The Breast Cancer Site Group (BCSG) of the National Cancer
Institute of Canada (NCIC) Clinical Trials Group (CTG) has
conducted a wide variety of clinical trials focussing on large phase
III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and
optimal delivery of adjuvant radiation therapy. The Group has also
fostered, together with the NCIC CTG Investigational New Drug
(IND) Program, a series of phase II and phase I/II studies which will
be carried through if possible, into the phase III setting.
Introduction
The Breast Cancer Site Group (BCSG) of the National
Cancer Institute of Canada (NCIC) Clinical Trials Group
(CTG) conducts clinical trials spanning a spectrum of
research designs. The Investigational New Drug (IND)
programme, chaired and co-chaired by Drs Elizabeth
Eisenhauer and Lesley Seymour, interfaces with the BCSG
to carry out phase II trials with a variety of new agents. The
BCSG strategy is to test new agents that may be suitable
for movement forward into larger phase III randomized trials
either in metastatic disease or, particularly, in the adjuvant
setting. The Group also targets phase I/II studies of
combinations of agents that may be moved forward into
phase III trials in the adjuvant, neoadjuvant, or metastatic
setting. It is the philosophy of the Group that large trials of
adjuvant therapy are most important in terms of translating
the maximum clinical benefit to the greatest number of
patients with breast cancer.
Currently, five very interesting trials are worthy of particular
mention.
MA.22
The NCIC CTG has conducted considerable investigation
into the taxanes and their role in the treatment of breast
cancer. Dr Maureen Trudeau in our group chaired one of
the first large phase II studies of taxotere in metastatic
breast cancer [1]. Published in the Journal of Clinical
Oncology, that trial showed a 55% (40% for 75 mg/m2
and 63% for 100 mg/m2) overall response rate to taxotere
in first-line therapy of metastatic breast cancer, and it was
one of the pivotol studies leading to approval of taxotere in
the therapy of metastatic breast cancer. Following on from
these data, Trudeau then chaired the MA.15 trial. A phase
I/II study conducted in patients with metastatic disease,
MA.15 explored the optimal doses of the combination of
taxotere and epirubicin with and without the use of colony-
stimulating factor. That trial, which was recently completed
[2,3], showed an extremely impressive overall response
rate of 70% for women treated with this combination.
Because this combination was so impressive, the Group
was interested in developing it further for potential use in
adjuvant therapy. With this in mind, we have moved
forward to a trial in the locally advanced and inflammatory
setting. It is felt that this more closely replicates the
adjuvant setting, in which disease may not be as
widespread as in metastatic disease, and hence higher
dosages may be tolerable.
The MA.22 study has a phase I/II design and is being
conducted in women with locally advanced and
inflammatory breast cancer. To date, four doses of
taxotere and epirubicin given at 3-week intervals have
been explored. Beginning at taxotere 75 mg/m2 and
epirubicin 75 mg/m2 with 6 mg pegfilgrastim, three
patients have been treated at each level, moving up to
75 mg/m2 taxotere and 120 mg/m2  epirubicin. At this
fourth level, two out of three patients developed dose
limiting toxicities. Thus, the maximum tolerated dosage has
been reached, and the next lower dose – taxotere
75 mg/m2 and epirubicin 105 mg/m2 – will be used for
further testing. The phase II portion of the trial is about to
begin and will involve the treatment of a total of
30 patients at dosages of epirubicin and taxotere of
105 mg/m2 and 75 mg/m2, respectively, with pegfilgrastim.
A second phase I/II protocol examining taxotere and
epirubicin given in a dose-dense manner every 2 weeks
will also be part of this trial. End-points will include overall
response rate, pathological complete response rate, and
disease-free and overall survival.
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MA.22 has provided a unique opportunity for translational
research directed at drug resistance to this unique
combination of drugs. Core biopsies of material that is fast
frozen are taken from each patient in the study before
therapy, after three cycles of therapy and after six cycles
of therapy. Dr Amadeo Parissenti, who has developed
gene signatures relating to taxotere and epirubicin
resistance [4], will be testing these specimens to
determine patterns of development of resistance during
combination therapy with these two drugs. We believe
that this model, in which multiple core biopsies are taken
and frozen, will prove extremely valuable for future studies,
in addition to providing data regarding resistance to
taxotere and epirubicin in this setting.
MA.27
The NCIC CTG, together with the North American
Intergroup (Cancer and Leukemia Group B, Eastern
Cooperative Oncology Group, Southwest Oncology
Group, and North Central Cancer Treatment Group),
European Organization for Research and Treatment of
Cancer and Breast International Group, recently
conducted the MA.17 trial, in which postmenopausal
women who had completed 4.5–6 years of tamoxifen in the
adjuvant setting were randomly assigned to receive either
5 years of letrozole 2.5 mg/day or placebo for 5 years. In
that trial, recent reports [5,6] have shown that the use of
letrozole resulted in significantly fewer breast cancer
events (local recurrence, distant recurrence, contralateral
breast cancer, death), and that this effect was significant in
both node-negative and node-positive subgroups
(Figs 1–3). In addition, in the node-positive subset overall
survival has been significantly improved by the use of
letrozole (ASCO 2004). Over a similar time period, reports
have indicated a better recurrence-free survival with
anastrozole than with tamoxifen when given to
postmenopausal women as adjuvant hormonal therapy
[7,8], and a recurrence-free survival advantage when either
anastrozole [9] or exemestane [10] was substituted for
tamoxifen after 2–3 years of adjuvant tamoxifen therapy.
These trials have established the aromatase inhibitors as
one of the standard options in the adjuvant treatment of
postmenopausal women with receptor-positive tumours.
Based on this body of work, the NCIC CTG has recently
initiated a trial that will be conducted in collaboration with
the North American Intergroup (Cancer and Leukemia
Group B, Eastern Cooperative Oncology Group,
Southwest Oncology Group, and North Central Cancer
Treatment Group), and with European Organization for
Research and Treatment of Cancer, International Breast
Cancer Study Group and Breast International Group. This
trial, MA.27, will randomly assign postmenopausal women
with oestrogen receptor and/or progesterone receptor
positive tumours in the adjuvant setting to receive
exemestane 25 mg/daily or anastrozole 1 mg/daily for
Figure 1
MA.17 results: disease-free survival by treatment duration. There is
increasing benefit in terms of estimated disease-free survival with
treatment duration. Adapted with permission from Goss and coworkers
[6].
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Figure 2
MA.17 results: disease-free survival over time. Adapted with
permission from Goss and coworkers [6].
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Figure 3
MA.17 results: total recurrences of breast cancer. *Patients may have
more than one recurrence site. Adapted with permission from Goss
and coworkers [6].
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5 years. Women will also be randomly assigned to receive
celecoxib 400 mg twice daily or placebo for 3 years.
Although celecoxib is currently being given for a 3-year
period, this may be extended to 5 years depending on
upcoming safety data, which is under review.
The concept of the trial is to determine which of the
nonsteroidal aromatase inhibitor anastrozole and the
steroidal aromatase inhibitor exemestane is superior in
terms of preventing recurrence and/or death from breast
cancer, and whether either has a superior toxicity profile.
There are now considerable data suggesting that all of the
aromatase inhibitors are associated with some increased
risk for development of osteoporosis and/or bone fracture.
However, it is believed that the steroidal aromatase
inhibitor may have less of an effect in this regard. In
addition, there are some data suggesting that exemestane
may be more likely to interact favourably with the
nonsteroidal anti-inflammatory celecoxib. Celecoxib has
been shown in preclinical models to have some anticancer
activity, and may interact differentially with steroidal and
nonsteroidal aromatase inhibitors. MA.27 is designed to
test all of these questions with regard to antitumour
efficacy and short, intermediate and long-term side
effects. The study will be accompanied by a variety of
correlative substudies, including studies of quality of life,
bone and lipid substudies, and basic science correlative
studies examining molecular profiles and other biomarkers
in relation to study results.
Investigational New Drug trials
In addition, the group is about to initiate two very
interesting IND trials. These trials, IND163 and IND164,
will study agents that have been selected for their unique
mechanisms of action and the possibility of favourable
antitumour activity.
The first of these trials, IND164, is a randomized phase II
trial examing the role of the anticlusterin, antisense
molecule OGX-011, together with taxotere, as first-line
chemotherapy for metastatic breast cancer. OGX-011 is
given as a 2-hour intravenous infusion weekly and
docetaxel 75 mg/m2 is given every 3 weeks as a 1-hour
intravenous infusion. The OGX-011 antisense, developed
in the laboratory of Dr Martin Gleeve in British Columbia,
has been shown to have activity in preclinical (Gleeve M,
personal communication) and clinical (Eisenhauer E,
personal communication) settings. It has been suggested
that OGX-011 may be particularly active in conjunction
with the taxanes. Thus, this trial may provide interesting
phase II data that could lead to further studies.
The second trial, IND163, is a randomized phase II trial of
two schedules of the oral rapamycin analogue RAD-001 in
first-line therapy for metastatic breast cancer. RAD-001
acts by inhibiting mammalian target of rapamycin (M-
TOR), a key signal transduction mediator. RAD-001 will
be given orally in a 4-week schedule either daily for
28 days or weekly (days 1, 8, 15 and 21).
MA.20
A fifth important study that is ongoing in the NCIC CTG
involves the comparison of regional nodal plus breast
versus breast-only radiation therapy in women who have
undergone breast conserving surgery. Randomized trials
have demonstrated that locoregional radiation therapy
following mastectomy for patients at high risk for
locoregional recurrence after intravenous
cyclophosphamide methotrexate and flourouracil or
hormonal therapy for short duration improves survival
[11,12]. Currently, the majority of women with early breast
cancer are treated with breast conserving surgery and
breast irradiation. Modern breast cancer treatments also
involve more frequent use of anthracycline-based
chemotherapy and long-duration hormonal therapy. It is
possible that, by adding regional irradiation, survival may
be improved compared with breast irradiation alone after
breast conserving surgery and systemic therapy. However,
regional irradiation may be associated with an increased
risk for pneumonitis, lymphoedema and, for patients with
left-sided cancer, cardiovascular disease. The goal of the
study is to determine whether adding regional irradiation
to modern systemic therapy improves survival with
acceptable limited toxicity in patients treated with breast
conservation therapy. This study will also of course
examine local and distant recurrence rates, cosmetic
results and quality of life. As of August 2004, over 1000
patients had been recruited to this trial of a proposed
sample size of 1800.
Conclusion
In summary, the NCIC CTG Breast Cancer Site Group is
committed to trials that will examine and develop new
agents with innovative mechanisms of action, which may
prove useful in the metastatic or adjuvant setting (IND163,
IND164); that will study interesting drugs or combinations
in the phase I/II setting, which may be moved forward for
therapy of adjuvant, neoadjuvant, or metastatic disease
(MA.22); that will explore optimal systemic regimens in the
adjuvant setting (MA.27); that will explore the role of local
and locoregional therapy in terms of their effect both on
locoregional recurrence and on distant recurrence and
overall survival (MA.20); and that will explore the optimal
multidisciplinary use of radiation, surgery and systemic
therapy in the treatment of breast cancer (MA.20).
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